The effects of medications used for the management of dyslipidemia on postprandial lipemia

Current Medicinal Chemistry

Volumn 16, Issue 2, 2009, Pages 203-217

  Tentolouris, N ^a   Eleftheriadou, I ^a   Katsilambros, N ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Apolipoproteins; Chylomicron; Chylomicron remnant; Fibrates; Postprandial lipemia; Remnant like particle; Statins; Triglyceride rich lipoprotein

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; BEZAFIBRATE; CIPROFIBRATE; CLOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAGNESIUM OXIDE; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; CHOLESTEROL ESTER TRANSFER PROTEIN; CHYLOMICRON; CLOFIBRIC ACID;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DYSLIPIDEMIA; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 4; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIPID METABOLISM; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; METABOLISM;

ANTILIPEMIC AGENTS; APOLIPOPROTEINS B; CHOLESTEROL ESTER TRANSFER PROTEINS; CHYLOMICRONS; CLOFIBRIC ACID; CORONARY ARTERY DISEASE; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; POSTPRANDIAL PERIOD; TRIGLYCERIDES;

EID: 62349133509     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709787002763     Document Type: Review

References (78)

1. De Man, F.H.; Cabezas, M.C.; Van Barlingen, H.H.; Erkelens, D.W.; de Bruin, T.W. Triglyceride-rich lipoproteins in non-insulindependent diabetes mellitus: Post-prandial metabolism and relation to premature atherosclerosis. Eur. J. Clin. Invest., 1996, 26, 89-108.
2. Hyson, D.; Rutledge, J.C.; Berglund, L. Postprandial lipemia and cardiovascular disease. Curr. Atheroscler. Rep., 2003, 5, 437-44.
3. Jansen, H. Hepatic lipase: Friend or foe and under what circumstances? Curr. Atheroscler. Rep., 2004, 6, 343-7.
4. Otarod, J.K.; Goldberg, I.J. Lipoprotein lipase and its role in regulation of plasma lipoproteins and cardiac risk. Curr. Atheroscler. Rep., 2004, 6, 335-42.
5. Cooper, A.D. Hepatic uptake of chylomicron remnants. J. Lipid Res., 1997, 38, 2173-92.
6. Krentz, A.J. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes. Metab., 2003, 5 (Suppl 1), S19-27.
7. Taskinen, M.R. LDL-cholesterol, HDL-cholesterol or triglycerides-which is the culprit? Diabetes Res. Clin. Pract., 2003, 61 (Suppl 1), S19-26.
8. Tan, K.C.; Cooper, M.B.; Ling, K.L.; Griffin, B.A.; Freeman, D.J.; Packard, C.J.; Shepherd, J.; Hales, C.N.; Betteridge, D.J. Fasting and postprandial determinants for the occurrence of small dense LDL species in non-insulin-dependent diabetic patients with and without hypertriglyceridaemia: The involvement of insulin, insulin precursor species and insulin resistance. Atherosclerosis, 1995, 113, 273-87.
9. Mead, J.R.; Irvine, S.A.; Ramji, D.P. Lipoprotein lipase: Structure, function, regulation, and role in disease. J. Mol. Med., 2002, 80, 753-69.
10. Karpe, F.; Steiner, G.; Uffelman, K.; Olivecrona, T.; Hamsten, A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis, 1994, 106, 83-97.
11. Zilversmit, D.B. Atherogenesis: A postprandial phenomenon. Circulation, 1979, 60, 473-85.
12. Hodis, H.N. Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis. Circulation, 1999, 99, 2852-4
13. Karpe, F. Postprandial lipemia - effect of lipid-lowering drugs. Atheroscler. Suppl., 2002, 3, 41-6.
14. Patsch, J.R.; Miesenbock, G.; Hopferwieser, T.; Muhlberger, V.; Knapp, E.; Dunn, J.K.; Gotto, A.M.; Jr.; Patsch, W. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler. Thromb., 1992, 12, 1336-45
15. Karpe, F. Postprandial lipoprotein metabolism and atherosclerosis. J. Intern. Med., 1999, 246, 341-55.
16. Slater, E.E.; MacDonald, J.S. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative. Drugs, 1988, 36 (Suppl 3), S72-82.
17. Alaupovic, P.; Hodis, H.N.; Knight-Gibson, C.; Mack, W.J.; La-Bree, L.; Cashin-Hemphill, L.; Corder, C.N.; Kramsch, D.M.; Blankenhorn, D.H. Effects of lovastatin on ApoA- and ApoB-containing lipoproteins. Families in a subpopulation of patients participating in the Monitored Atherosclerosis Regression Study (MARS). Arterioscler. Thromb., 1994, 14, 1906-13.
18. Le, N.A.; Innis-Whitehouse, W.; Li, X.; Bakker-Arkema, R.; Black, D.; Brown, W.V. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: Effect of triglyceride reductions with atorvastatin. Metabolism, 2000, 49, 167-77.
19. Arad, Y.; Ramakrishnan, R.; Ginsberg, H.N. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoBcontaining lipoproteins: Implications for the pathophysiology of apoB production. J. Lipid Res., 1990, 31, 567-82.
20. Stuyt, P.M.; Mol, M.J.; Stalenhoef, A.F.; Demacker, P.N.; Van 't Laar, A. Simvastatin in the effective reduction of plasma lipoprotein levels in familial dysbetalipoproteinemia (type III hyperlipoproteinemia). Am. J. Med., 1990, 88, 42N-45N.
21. Vega, G.L.; Krauss, R.M.; Grundy, S.M. Pravastatin therapy in primary moderate hypercholesterolaemia: Changes in metabolism of apolipoprotein B-containing lipoproteins. J. Intern. Med., 1990, 227, 81-94.
22. Arad, Y.; Ramakrishnan, R.; Ginsberg, H.N. Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: Evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism, 1992, 41, 487-93.
23. Cuchel, M.; Schaefer, E.J.; Millar, J.S.; Jones, P.J.; Dolnikowski, G.G.; Vergani, C.; Lichtenstein, A.H. Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males. Arterioscler. Thromb. Vasc. Biol., 1997, 17, 1910-7.
24. Berglund, L.; Witztum, J.L.; Galeano, N.F.; Khouw, A.S.; Ginsberg, H.N.; Ramakrishnan, R. Three-fold effect of lovastatin treatment on low density lipoprotein metabolism in subjects with hyperlipidemia: Increase in receptor activity, decrease in apoB production, and decrease in particle affinity for the receptor. Results from a novel triple-tracer approach. J. Lipid Res., 1998, 39, 913-24.
25. Sasaki, S.; Kuwahara, N.; Kunitomo, K.; Harada, S.; Yamada, T.; Azuma, A.; Takeda, K.; Nakagawa, M. Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia. Am. J. Cardiol., 2002, 89, 386-9.
26. Stein, D.T.; Devaraj, S.; Balis, D.; Adams-Huet, B.; Jialal, I. Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol., 2001, 21, 2026-31.
27. Forster, L.F.; Stewart, G.; Bedford, D.; Stewart, J.P.; Rogers, E.; Shepherd, J.; Packard, C.J.; Caslake, M.J. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.Atherosclerosis, 2002, 164, 129-45.
28. Weintraub, M.S.; Eisenberg, S.; Breslow, J.L. Lovastatin reduces postprandial lipoprotein levels in hypercholesterolaemic patients with mild hypertriglyceridaemia. Eur. J. Clin. Invest., 1989, 19, 480-5.
29. Cianflone, K.; Bilodeau, M.; Davignon, J.; Sniderman, A.D. Modulation of chylomicron remnant metabolism by an hepatic hydroxymethylglutaryl coenzyme A reductase inhibitor. Metabolism, 1990, 39, 274-80.
30. Cabezas, M.C.; de Bruin, T.W.; Kock, L.A.; Kortlandt, W.; Van Linde-Sibenius Trip, M.; Jansen, H.; Erkelens, D.W. Simvastatin improves chylomicron remnant removal in familial combined hyperlipidemia without changing chylomicron conversion. Metabolism, 1993, 42, 497-503.
31. Simo, I.E.; Yakichuk, J.A.; Ooi, T.C. Effect of gemfibrozil and lovastatin on postprandial lipoprotein clearance in the hypoalphalipoproteinemia and hypertriglyceridemia syndrome. Atherosclerosis, 1993, 100, 55-64.
32. Castro Cabezas, M.; Erkelens, D.W.; Kock, L.A.; De Bruin, T.W. Postprandial apolipoprotein B100 and B48 metabolism in familial combined hyperlipidaemia before and after reduction of fasting plasma triglycerides. Eur. J. Clin. Invest., 1994, 24, 669-78.
33. Bhatnagar, D.; Durrington, P.N.; Kumar, S.; Mackness, M.I.; Dean, J.; Boulton, A.J. Effect of treatment with a hydroxymethylglutaryl coenzyme A reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester transfer activity in patients with NIDDM. Diabetes, 1995, 44, 460-5.
34. O'Keefe, J.H.; Jr.; Harris, W.S.; Nelson, J.; Windsor, S.L. Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. Am. J. Cardiol., 1995, 76, 480-4.
35. Noutsou, M.; Georgopoulos, A. Effects of simvastatin on fasting and postprandial triglyceride-rich lipoproteins in patients with type I diabetes mellitus. J. Diabetes Complications, 1999, 13, 98-104.
36. Parhofer, K.G.; Barrett, P.H.; Schwandt, P. Atorvastatin improves postprandial lipoprotein metabolism in normolipidemlic subjects. J. Clin. Endocrinol. Metab., 2000, 85, 4224-30.
37. Twickler, T.B.; Dallinga-Thie, G.M.; de Valk, H.W.; Schreuder, P.C.; Jansen, H.; Cabezas, M.C.; Erkelens, D.W. High dose of simvastatin normalizes postprandial remnant-like particle response in patients with heterozygous familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 2422-7.
38. Sheu, W.H.; Jeng, C.Y.; Lee, W.J.; Lin, S.Y.; Pei, D.; Chen, Y.T. Simvastatin treatment on postprandial hypertriglyceridemia in type 2 diabetes mellitus patients with combined hyperlipidemia. Metabolism, 2001, 50, 355-9.
39. Vansant, G.; Mertens, A.; Muls, E. The effect of atorvastatin on postprandial lipaemia in overweight or obese women homozygous for apo E3. Acta Cardiol., 2001, 56, 149-54.
40. Boquist, S.; Karpe, F.; Danell-Toverud, K.; Hamsten, A. Effects of atorvastatin on postprandial plasma lipoproteins in postinfarction patients with combined hyperlipidaemia. Atherosclerosis, 2002, 162, 163-70.
41. Guerin, M.; Egger, P.; Le Goff, W.; Soudant, C.; Dupuis, R.; Chapman, M.J. Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIb hyperlipidemia. J. Clin. Endocrinol. Metab., 2002, 87, 4991-5000.
42. McLaughlin, T.; Abbasi, F.; Lamendola, C.; Leary, E.; Reaven, G.M. Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia. Metabolism, 2002, 51, 1355-9.
43. Schaefer, E.J.; McNamara, J.R.; Tayler, T.; Daly, J.A.; Gleason, J.A.; Seman, L.J.; Ferrari, A.; Rubenstein, J.J. Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects. Am. J. Cardiol., 2002, 90, 689-96.
44. Parhofer, K.G.; Laubach, E.; Barrett, P.H. Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients. J. Lipid Res., 2003, 44, 1192-8.
45. Verseyden, C.; Meijssen, S.; van Dijk, H.; Jansen, H.; Castro Cabezas, M. Effects of atorvastatin on fasting and postprandial complement component 3 response in familial combined hyperlipidemia. J. Lipid Res., 2003, 44, 2100-8.
46. Westphal, S.; Wiens, L.; Guttler, K.; Dierkes, J.; Luley, C. Chylomicron remnants of various sizes are lowered more effectively by fenofibrate than by atorvastatin in patients with combined hyperlipidemia. Atherosclerosis, 2003, 171, 369-77.
47. Castro Cabezas, M.; Verseyden, C.; Meijssen, S.; Jansen, H.; Erkelens, D.W. Effects of atorvastatin on the clearance of triglyceride-rich lipoproteins in familial combined hyperlipidemia. J. Clin. Endocrinol. Metab., 2004, 89, 5972-80.
48. Lamendola, C.; Abbasi, F.; Chu, J.W.; Hutchinson, H.; Cain, V.; Leary, E.; McLaughlin, T.; Stein, E.; Reaven, G. Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia. Am. J. Cardiol., 2005, 95, 189-93.
49. Iovine, C.; Lilli, S.; Gentile, A.; Patti, L.; Di Marino, L.; Cipriano, P.; Riccardi, G.; Rivellese, A.A. Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia. Eur. J. Clin. Invest., 2006, 36, 560-5.
50. Kolovou, G.D.; Anagnostopoulou, K.K.; Salpea, K.D.; Daskalopoulou, S.S.; Mikhailidis, D.P. The effect of statins on postprandial lipemia. Curr. Drug Targets, 2007, 8, 551-60.
51. Grundy, S.M.; Vega, G.L. Fibric acids: Effects on lipids and lipoprotein metabolism. Am. J. Med., 1987, 83, 9-20.
52. de Man, F.H.; de Beer, F.; van der Laarse, A.; Jansen, H.; Leuven, J.A.; Souverijn, J.H.; Vroom, T.F.; Schoormans, S.C.; Fruchart, J.C.; Havekes, L.M.; Smelt, A.H. The hypolipidemic action of bezafibrate therapy in hypertriglyceridemia is mediated by upregulation of lipoprotein lipase: no effects on VLDL substrate affinity to lipolysis or LDL receptor binding. Atherosclerosis, 2000, 153, 363-71.
53. Cottrell, D.A.; Marshall, B.J.; Falko, J.M. Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome. Curr. Opin. Cardiol., 2003, 18, 301-8.
54. Saku, K.; Gartside, P.S.; Hynd, B.A.; Kashyap, M.L. Mechanism of action of gemfibrozil on lipoprotein metabolism. J. Clin. Invest., 1985, 75, 1702-12.
55. Avogaro, A.; Piliego, T.; Catapano, A.; Miola, M.; Tiengo, A. The effect of gemfibrozil on lipid profile and glucose metabolism in hypertriglyceridaemic well-controlled non-insulin-dependent diabetic patients. For the Gemfibrozil Study Group. Acta Diabetol., 1999, 36, 27-33.
56. Kesaniemi, Y.A.; Grundy, S.M. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man. JAMA, 1984, 251, 2241-6.
57. Steinmetz, A. Treatment of diabetic dyslipoproteinemia. Exp. Clin. Endocrinol. Diabetes, 2003, 111, 239-45.
58. Vega, G.L.; Cater, N.B.; Hadizadeh, D.R.; 3rd, Meguro, S.; Grundy, S.M. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome. Clin. Pharmacol. Ther., 2003, 74, 236-44.
59. Weintraub, M.S.; Eisenberg, S.; Breslow, J.L. Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil. J. Clin. Invest., 1987, 79, 1110-9.
60. Simpson, H.S.; Williamson, C.M.; Olivecrona, T.; Pringle, S.; Maclean, J.; Lorimer, A.R.; Bonnefous, F.; Bogaievsky, Y.; Packard, C.J.; Shepherd, J. Postprandial lipemia, fenofibrate and coronary artery disease. Atherosclerosis, 1990, 85, 193-202.
61. Bhatnagar, D.; Durrington, P.N.; Mackness, M.I.; Arrol, S.; Winocour, P.H.; Prais, H. Effects of treatment of hypertriglyceridaemia with gemfibrozil on serum lipoproteins and the transfer of cholesteryl ester from high density lipoproteins to low density lipoproteins. Atherosclerosis, 1992, 92, 49-57.
62. Syvanne, M.; Vuorinen-Markkola, H.; Hilden, H.; Taskinen, M.R. Gemfibrozil reduces postprandial lipemia in non-insulin-dependent diabetes mellitus. Arterioscler. Thromb., 1993, 13, 286-95.
63. Foger, B.; Trobinger, G.; Ritsch, A.; Lechleitner, M.; Hopferwieser, T.; Menzel, H.J.; Utermann, G.; Pfeiffer, K.P.; Patsch, J.R. Treatment of primary mixed hyperlipidemia with etophylline clofibrate: Effects on lipoprotein-modifying enzymes, postprandial lipoprotein metabolism, and lipoprotein distribution and composition. Atherosclerosis, 1995, 117, 253-61.
64. Jones, P.H.; Pownall, H.J.; Patsch, W.; Herd, J.A.; Farmer, J.A.; Payton-Ross, C.; Kimball, K.T.; Gotto, A.M.; Morrisett, J.D. Effect of gemfibrozil on levels of lipoproteina in type II hyperlipoproteinemic subjects. J. Lipid Res., 1996, 37, 1298-308.
65. Attia, N.; Durlach, V.; Roche, D.; Paul, J.L.; Soni, T.; Zahouani, A.; Landron, F.; Labrousse, F.; Leutenegger, M.; Girard-Globa, A. Post-prandial metabolism of triglyceride-rich lipoproteins in noninsulin-dependent diabetic patients before and after bezafibrate treatment. Eur. J. Clin. Invest., 1997, 27, 55-63
66. Lewis, G.F.; Uffelman, K.D.; Lamarche, B.; Cabana, V.G.; Getz, G.S. Production of small high-density lipoprotein particles after stimulation of in vivo lipolysis in hypertriglyceridemic individuals: Studies before and after triglyceride-lowering therapy. Metabolism, 1998, 47, 234-42.
67. Weintraub, M.S.; Charach, G.; Grosskopf, I. Effects of fibric acid derivatives and metformin on postprandial lipemia. Atherosclerosis, 1998, 141 (Suppl 1), S71-5.
68. Attia, N.; Durlach, V.; Cambilleau, M.; Roche, D.; Girard-Globa, A. Postprandial concentrations and distribution of apo C-III in type 2 diabetic patients. Effect Of bezafibrate treatment. Atherosclerosis, 2000, 149, 427-33.
69. Autran, D.; Attia, N.; Dedecjus, M.; Durlach, V.; Girard-Globa, A. Postprandial reverse cholesterol transport in type 2 diabetic patients: effect of a lipid lowering treatment. Atherosclerosis, 2000, 153, 453-60.
70. Evans, M.; Anderson, R.A.; Graham, J.; Ellis, G.R.; Morris, K.; Davies, S.; Jackson, S.K.; Lewis, M.J.; Frenneaux, M.P.; Rees, A. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation, 2000, 101, 1773-9.
71. Genest, J.; Jr.; Nguyen, N.H.; Theroux, P.; Davignon, J.; Cohn, J.S. Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state. J. Cardiovasc. Pharmacol., 2000, 35, 164-72.
72. Ogawa, S.; Takeuchi, K.; Sugimura, K.; Fukuda, M.; Lee, R.; Ito, S.; Sato, T. Bezafibrate reduces blood glucose in type 2 diabetes mellitus. Metabolism, 2000, 49, 331-4.
73. Cavallero, E.; Dachet, C.; Assadolahi, F.; Martin, C.; Navarro, N.; Ansquer, J.C.; Corda, C.; Foucher, C.; Juhan-Vague, I.; Jacotot, B. Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control. Atherosclerosis, 2003, 166, 151-61.
74. Ooi, T.C.; Cousins, M.; Ooi, D.S.; Nakajima, K.; Edwards, A.L. Effect of fibrates on postprandial remnant-like particles in patients with combined hyperlipidemia. Atherosclerosis, 2004, 172, 375-82.
75. Superko, H.R.; Berneis, K.K.; Williams, P.T.; Rizzo, M.; Wood, P.D. Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A. Am. J. Cardiol., 2005, 96, 1266-72.
76. Kolovou, G.D.; Kostakou, P.M.; Anagnostopoulou, K.K.; Cokkinos, D.V. Therapeutic effects of fibrates in postprandial lipemia. Am. J. Cardiovasc. Drugs, 2008, 8, 243-55.
77. Cohn, J.S.; Marcoux, C.; Davignon, J. Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins. Arterioscler. Thromb. Vasc. Biol., 1999, 19, 2474-86.
78. Katsilambros, N. Postprandial triglyceridaemia. Diabet. Med., 1995, 12, 451-2.